JP Morgan Chase
SAGE

JP Morgan Chase’s Sage Therapeutics SAGE Stock Holding History

JP Morgan Chase’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,000
Closed -$407K – 7676
2024
Q4 		$407K Buy
+75,000
New +$459K ﹤0.01% 5147
2021
Q3 		– Sell
-23,700
Closed -$1.35M – 6747
2021
Q2 		$1.35M Buy
+23,700
New +$1.68M ﹤0.01% 4094
2021
Q1 		– Sell
-100
Closed -$9K – 6312
2020
Q4 		$9K Hold
100
– – ﹤0.01% 5402
2020
Q3 		$6K Sell
100
-65,900
-100% -$3.34M ﹤0.01% 5313
2020
Q2 		$2.74M Buy
+66,000
New +$2.4M ﹤0.01% 2895
2020
Q1 		– Sell
-75,000
Closed -$5.41M – 5669
2019
Q4 		$5.41M Buy
+75,000
New +$9.23M ﹤0.01% 2608
2019
Q2 		– Sell
-35,700
Closed -$5.68M – 5979
2019
Q1 		$5.68M Buy
35,700
+34,600
+3,145% +$5.01M ﹤0.01% 2486
2018
Q4 		$105K Hold
1,100
– – ﹤0.01% 4833
2018
Q3 		$155K Buy
+1,100
New +$170K ﹤0.01% 4780
2017
Q4 		– Sell
-3,000
Closed -$189K – 5559
2017
Q3 		$189K Buy
+3,000
New +$236K ﹤0.01% 4123

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's SAGE Position: Q3 2025 in Review

JP Morgan Chase sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 132,912 shares — an estimated $1.21M sold.

JP Morgan Chase first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $165M in Q2 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • JP Morgan Chase reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 132,912 Sage Therapeutics shares in Q3 2025, an estimated $1.21M.
  • JP Morgan Chase first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
  • JP Morgan Chase's Sage Therapeutics position peaked at $165M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.